Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir-Reference-Cited by-同舟云学术

Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir

Published:2014-02-12 Issue:5 Volume:57 Page:2013-2032
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Belema Makonen,Nguyen Van N.,Bachand Carol¹,Deon Dan H.¹,Goodrich Jason T.,James Clint A.¹,Lavoie Rico¹,Lopez Omar D.,Martel Alain¹,Romine Jeffrey L.,Ruediger Edward H.¹,Snyder Lawrence B.,St. Laurent Denis R.,Yang Fukang,Zhu Juliang,Wong Henry S.,Langley David R.,Adams Stephen P.,Cantor Glenn H.²,Chimalakonda Anjaneya²,Fura Aberra³,Johnson Benjamin M.,Knipe Jay O.,Parker Dawn D.,Santone Kenneth S.,Fridell Robert A.,Lemm Julie A.,O’Boyle Donald R.,Colonno Richard J.,Gao Min,Meanwell Nicholas A.,Hamann Lawrence G.

Affiliation:

1. Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute , 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1

2. Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development , 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States

3. Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development , Route 206 and Province Line Road, Princeton, New Jersey 08543, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm401836p

Reference37 articles.

1. Simeprevir: First Global Approval

2. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

3. c Gilead Sciences, Inc. U.S. Food and Drug Administration approves Gilead’s SovaldiTM (sofosbuvir) for the treatment of chronic hepatitis C. http://www.gilead.com/news/press-releases, Dec. 6, 2013.

4. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is Daclatasvir a Suitable Substitute for Amphotericin B in the Treatment of Mucormycosis when Amphotericin B is Scarce?;Current Drug Research Reviews;2024-03

2. Design Principles for Balancing Lipophilicity and Permeability in beyond Rule of 5 Space;ChemMedChem;2023-11-30

3. The rise of degrader drugs;Cell Chemical Biology;2023-08

4. Successes in antiviral drug discovery: a tribute to Nick Meanwell;Medicinal Chemistry Research;2023-06-08

5. Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells;Molecular Cancer Therapeutics;2023-01-11